FibroGen (NASDAQ:FGEN) Issues Earnings Results

by · The Cerbat Gem

FibroGen (NASDAQ:FGEN – Get Free Report) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($1.61) earnings per share for the quarter, topping the consensus estimate of ($4.01) by $2.40, Zacks reports.

FibroGen Trading Down 0.3%

FGEN traded down $0.03 during trading on Monday, reaching $11.00. 42,197 shares of the company were exchanged, compared to its average volume of 68,750. FibroGen has a 52 week low of $4.50 and a 52 week high of $21.94. The firm has a 50 day moving average of $11.42 and a 200 day moving average of $9.02. The stock has a market cap of $44.48 million, a P/E ratio of -28.95 and a beta of 0.75.

Analyst Upgrades and Downgrades

A number of research firms recently commented on FGEN. HC Wainwright reiterated a “buy” rating and issued a $43.00 price target on shares of FibroGen in a research note on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of FibroGen in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded FibroGen from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $43.00.

Get Our Latest Research Report on FibroGen

Hedge Funds Weigh In On FibroGen

An institutional investor recently raised its position in FibroGen stock. Vanguard Group Inc. boosted its position in FibroGen, Inc (NASDAQ:FGEN – Free Report) by 3.5% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 184,244 shares of the biopharmaceutical company’s stock after purchasing an additional 6,204 shares during the quarter. Vanguard Group Inc. owned about 4.56% of FibroGen worth $2,257,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

(Get Free Report)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.

Further Reading